ILD
MCID: INT066
MIFTS: 63

Interstitial Lung Disease (ILD)

Categories: Blood diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Interstitial Lung Disease

MalaCards integrated aliases for Interstitial Lung Disease:

Name: Interstitial Lung Disease 12 76 53 15
Lung Diseases, Interstitial 44 73
Ild 12 15
Lung Diseases Interstitial 55
Interstitial Lung Diseases 43

Classifications:



External Ids:

Disease Ontology 12 DOID:3082
ICD10 33 J84.9
MeSH 44 D017563
SNOMED-CT 68 64667001
UMLS 73 C0206062

Summaries for Interstitial Lung Disease

NIH Rare Diseases : 53 Interstitial lung diseases (ILDs) are a large group of disorders characterized by thickening of the walls between the alveoli, increased production and buildup of collagen, and pulmonary fibrosis (progressive scarring of lung tissue). The scarring eventually affects the ability to breathe and get enough oxygen into the bloodstream. Symptoms typically include shortness of breath and a dry cough. There are numerous possible causes of ILD, including connective tissue disorders, autoimmune diseases (e.g. rheumatoid arthritis), occupational exposures (such as asbestos), infection, and many drugs. Specific diseases leading to ILD may include sarcoidosis, pulmonary Langerhans cell histiocytosis, and eosinophilic pulmonary diseases. The list of substances and conditions that can lead to ILD is long. However, in many cases, the cause is not known. Some cases of unknown cause that share similar characteristics are called idiopathic interstitial pneumonias. Lung scarring that occurs in ILD is permanent. However, some treatments may temporarily improve symptoms or slow the disease's progress. Treatment options may include various medications, oxygen therapy, pulmonary rehabilitation, and as a last resort, lung transplantation.

MalaCards based summary : Interstitial Lung Disease, also known as lung diseases, interstitial, is related to desquamative interstitial pneumonia and surfactant dysfunction, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Interstitial Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pirfenidone and Bosentan have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

MedlinePlus : 43 Interstitial lung disease is the name for a large group of diseases that inflame or scar the lungs. The inflammation and scarring make it hard to get enough oxygen. The scarring is called pulmonary fibrosis. Breathing in dust or other particles in the air is responsible for some types of interstitial lung diseases. Specific types include Black lung disease among coal miners, from inhaling coal dust Farmer's lung, from inhaling farm dust Asbestosis, from inhaling asbestos fibers Siderosis, from inhaling iron from mines or welding fumes Silicosis, from inhaling silica dust Other causes include autoimmune diseases or occupational exposures to molds, gases, or fumes. Some types of interstitial lung disease have no known cause. Treatment depends on the type of exposure and the stage of the disease. It may involve medicines, oxygen therapy, or a lung transplant in severe cases.

Wikipedia : 76 Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of lung diseases... more...

Related Diseases for Interstitial Lung Disease

Diseases related to Interstitial Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 375)
# Related Disease Score Top Affiliating Genes
1 desquamative interstitial pneumonia 32.9 ABCA3 MUC5B SFTPC
2 surfactant dysfunction 32.7 ABCA3 SFTPB SFTPC
3 pulmonary fibrosis 32.2 CCL2 EDN1 IL1B MUC5B SFTPC SFTPD
4 extrinsic allergic alveolitis 32.2 CCL2 CCL5 CXCL8 IL1B SFTPD
5 bagassosis 31.8 CXCL8 IL1B
6 pneumoconiosis 31.4 CCL2 CXCL8 IL1B MUC5B TGFB1 TNF
7 connective tissue disease 31.2 EDN1 IL1A MUC1 SFTPD TNF
8 arthritis 31.0 CCL2 CXCL8 IL1A IL1B TGFB1 TNF
9 systemic scleroderma 30.9 EDN1 SFTPD TGFB1
10 rheumatoid arthritis 30.9 CCL2 CCL5 CXCL8 IL1A IL1B TGFB1
11 bronchiolitis 30.8 CCL5 CXCL8 MUC5B TNF
12 lung disease 30.6 ABCA3 CCL2 CCL5 CXCL8 EDN1 EGFR
13 pleuroparenchymal fibroelastosis 30.5 MUC1 SFTPD
14 pneumonia 30.3 CCL2 CCL5 CXCL8 IL1B MUC5B SFTPB
15 respiratory failure 30.3 CXCL8 NKX2-1 SFTPB SFTPC SFTPD TNF
16 pulmonary disease, chronic obstructive 30.2 CCL2 CCL5 CXCL8 SFTPB SFTPD TGFB1
17 sleep apnea 30.2 CXCL8 EDN1 IL1B TNF
18 lung cancer susceptibility 3 30.1 EGFR MUC1 NKX2-1 SFTPB SFTPC TGFB1
19 temporal arteritis 30.0 CCL2 CCL5 TNF
20 idiopathic interstitial pneumonia 30.0 CCL2 CXCL8 EDN1 MUC5B SFTPC SFTPD
21 pulmonary eosinophilia 30.0 CCL17 CCL5 SFTPD
22 eosinophilic pneumonia 30.0 CCL17 CCL5 SFTPD
23 neonatal respiratory failure 30.0 ABCA3 SFTPB SFTPC
24 aspergillosis 30.0 CCL17 SFTPD TNF
25 bacterial pneumonia 29.9 CXCL8 SFTPB SFTPD
26 pulmonary alveolar proteinosis 29.9 CCL2 SFTPB SFTPC SFTPD
27 rheumatoid lung disease 29.9 IL1B MUC1 TNF
28 pleurisy 29.9 CCL2 CXCL8 TNF
29 uveitis 29.8 CCL2 IL1A TNF
30 pulmonary sarcoidosis 29.8 CCL2 CCL5 SFTPD TNF
31 peritonitis 29.7 CCL2 CXCL8 IL1B TNF
32 pulmonary edema 29.7 CXCL8 EDN1 IL1B TNF
33 viral infectious disease 29.6 CCL5 CXCL8 IFIH1 IL1B TNF
34 sarcoidosis 1 29.6 CCL17 CCL2 IL1B TNF
35 acute respiratory distress syndrome 29.6 CXCL8 IL1B SFTPB SFTPC SFTPD TNF
36 dermatitis, atopic 29.5 CCL17 CCL2 CCL5 CXCL8 TNF
37 psoriasis 29.3 CCL17 CCL2 CCL5 CXCL8 IFIH1 IL1A
38 pulmonary fibrosis, idiopathic 29.2 ABCA3 CCL17 CCL2 CCL5 CXCL8 EDN1
39 asthma 28.9 CCL17 CCL2 CCL5 CXCL8 EDN1 IL1A
40 interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital 12.6
41 children's interstitial lung disease 12.6
42 drug or radiation exposure-related interstitial lung disease 12.2
43 respiratory bronchiolitis-interstitial lung disease syndrome 12.2
44 interstitial pneumonitis, desquamative, familial 11.9
45 surfactant metabolism dysfunction, pulmonary, 2 11.8
46 autoimmune interstitial lung, joint, and kidney disease 11.8
47 antisynthetase syndrome 11.5
48 dermatomyositis 11.5
49 surfactant metabolism dysfunction, pulmonary, 1 11.5
50 surfactant metabolism dysfunction, pulmonary, 3 11.5

Graphical network of the top 20 diseases related to Interstitial Lung Disease:



Diseases related to Interstitial Lung Disease

Symptoms & Phenotypes for Interstitial Lung Disease

UMLS symptoms related to Interstitial Lung Disease:


hemoptysis, snoring, coughing

GenomeRNAi Phenotypes related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR TGFB1
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR TGFB1

MGI Mouse Phenotypes related to Interstitial Lung Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.18 EDN1 EGFR IFIH1 IL1B ITGA3 MUC5B
2 homeostasis/metabolism MP:0005376 10.17 ABCA3 EDN1 EGFR IFIH1 IL1A IL1B
3 cardiovascular system MP:0005385 10.13 ABCA3 EDN1 EGFR IL1A IL1B ITGA3
4 hematopoietic system MP:0005397 10.11 CCL17 CCL5 EGFR IFIH1 IL1A IL1B
5 immune system MP:0005387 10.07 CCL17 CCL2 CCL5 EGFR IFIH1 IL1A
6 mortality/aging MP:0010768 10 ABCA3 EDN1 EGFR IFIH1 IL1B ITGA3
7 neoplasm MP:0002006 9.56 EGFR IL1A IL1B ITGA3 NKX2-1 SFTPC
8 respiratory system MP:0005388 9.32 ABCA3 EGFR ITGA3 MUC5B NKX2-1 SFTPB

Drugs & Therapeutics for Interstitial Lung Disease

Drugs for Interstitial Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4,Phase 2,Not Applicable 53179-13-8 40632
2
Bosentan Approved, Investigational Phase 4,Phase 2,Phase 3 147536-97-8 104865
3
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 78919-13-8 6443959
4
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
5
Nintedanib Approved Phase 4,Phase 3,Phase 1 656247-17-5 56843413
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Methylprednisolone Approved, Vet_approved Phase 4,Early Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Early Phase 1 50-24-8 5755
10
Prednisolone phosphate Approved, Vet_approved Phase 4,Early Phase 1 302-25-0
11
Methylprednisolone hemisuccinate Approved Phase 4,Early Phase 1 2921-57-5
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
13
Prednisolone hemisuccinate Experimental Phase 4,Early Phase 1 2920-86-7
14 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Analgesics Phase 4,Phase 2,Not Applicable
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Not Applicable
20 Endothelin Receptor Antagonists Phase 4,Phase 2,Phase 3
21 Antihypertensive Agents Phase 4,Phase 2,Phase 3
22 Vasodilator Agents Phase 4,Phase 2,Phase 3,Not Applicable
23 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3
24 Calamus Phase 4,Not Applicable
25 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Not Applicable,Early Phase 1
26 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
27 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 3
32 Potassium Channel Blockers Phase 4
33 Cytochrome P-450 Enzyme Inhibitors Phase 4
34 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
35 Sodium Channel Blockers Phase 4,Phase 2,Phase 3
36 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
37 Cytochrome P-450 CYP3A Inhibitors Phase 4
38 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
39 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
40 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
41 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Autonomic Agents Phase 4,Phase 1,Early Phase 1
43 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Sildenafil Citrate Phase 4,Not Applicable 171599-83-0
45 Phosphodiesterase Inhibitors Phase 4,Phase 3,Not Applicable
46 Citrate Phase 4,Not Applicable
47 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Not Applicable
48 Anesthetics, Inhalation Phase 4,Phase 1
49 Anesthetics, General Phase 4,Phase 1
50 Narcotics Phase 4

Interventional clinical trials:

(show top 50) (show all 311)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
3 Pulmonary Rehabilitation in Interstitial Lung Diseases Completed NCT00882817 Phase 4
4 Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) Completed NCT02286063 Phase 4 Ambulatory Oxygen
5 Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
6 Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Completed NCT01199081 Phase 4 Dronedarone
7 Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep Recruiting NCT02150616 Phase 4 Oxygen;Sham oxygen (room air)
8 Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease Recruiting NCT02622022 Phase 4 Morphine hydrochloride
9 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
10 Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT03717012 Phase 4 Nintedanib
11 Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance Active, not recruiting NCT02143687 Phase 4 Oxygen;Sham oxygen (room air)
12 Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Withdrawn NCT00625079 Phase 4 sildenafil
13 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Withdrawn NCT00625469 Phase 4 bosentan
14 Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection Unknown status NCT00841750 Phase 3
15 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
16 Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
17 Open-label Study With Bosentan in Interstitial Lung Disease Completed NCT00319033 Phase 2, Phase 3 bosentan
18 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
19 Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Completed NCT02896205 Phase 3 Mycophenolate mofetil;Placebo
20 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Completed NCT02597933 Phase 3 Nintedanib;Placebo
21 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
22 BUILD 3: Bosentan Use in Interstitial Lung Disease Completed NCT00391443 Phase 3 Bosentan;Placebo
23 Rituximab in Rheumatoid Arthritis Lung Disease Completed NCT00578565 Phase 3 Rituximab
24 Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization Completed NCT01973998 Phase 3 Roflumilast;Placebo
25 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
26 A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy Completed NCT01955824 Phase 2, Phase 3 1% lignocaine;2% lignocaine
27 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
28 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
29 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 Completed NCT00631475 Phase 3 Bosentan
30 Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases Recruiting NCT02990286 Phase 3 Rituximab;Placebo of Rituximab;Mycophenolate Mofetil
31 CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Recruiting NCT03726398 Phase 2, Phase 3 Opsumit 10 Mg Tablet
32 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
33 A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis. Recruiting NCT03313180 Phase 3 Nintedanib
34 Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Recruiting NCT02630316 Phase 2, Phase 3 Inhaled Treprostinil;Placebo
35 Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease Recruiting NCT03241420 Phase 3
36 Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Recruiting NCT03386539 Phase 3 Everolimus;Tacrolimus;Mycophenolate Mofetil
37 Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease Active, not recruiting NCT01570764 Phase 3 Cyclophosphamide;Placebo
38 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Active, not recruiting NCT02999178 Phase 3 Nintedanib;Placebo
39 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Active, not recruiting NCT02474355 Phase 3 AZD9291 Dosing
40 Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01959100 Phase 3 Azithromycin;Placebo
41 An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Enrolling by invitation NCT02633293 Phase 2, Phase 3 Inhaled Treprostinil
42 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease Not yet recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
43 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
44 Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure Terminated NCT03262571 Phase 3
45 (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF Terminated NCT00768300 Phase 3 Ambrisentan;Placebo
46 GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases Terminated NCT01257802 Phase 3 depot leuprolide acetate 3.75 mg;Placebo
47 MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Unknown status NCT02543073 Phase 1, Phase 2 AZM;Glucocorticoid
48 Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease Unknown status NCT01450644 Phase 2
49 Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Unknown status NCT02370693 Phase 2 Bortezomib;Placebo;Mycophenolate mofetil
50 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo

Search NIH Clinical Center for Interstitial Lung Disease

Cochrane evidence based reviews: lung diseases, interstitial

Genetic Tests for Interstitial Lung Disease

Anatomical Context for Interstitial Lung Disease

MalaCards organs/tissues related to Interstitial Lung Disease:

41
Lung, Testes, Bone, Bone Marrow, Heart, B Cells, T Cells

Publications for Interstitial Lung Disease

Articles related to Interstitial Lung Disease:

(show top 50) (show all 1767)
# Title Authors Year
1
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. ( 30456167 )
2019
2
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. ( 29936475 )
2018
3
Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease. ( 29353024 )
2018
4
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. ( 29914454 )
2018
5
Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. ( 28379478 )
2018
6
Exertional Oxygen Requirements During Exercise Training in Advanced Interstitial Lung Disease. ( 29952810 )
2018
7
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. ( 29382380 )
2018
8
Screening for pulmonary hypertension in interstitial lung disease: Many reasons to ECHO! ( 29415370 )
2018
9
Safety of performing transbronchial lung cryobiopsy on hospitalized patients with interstitial lung disease. ( 29957284 )
2018
10
The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. ( 29977547 )
2018
11
Unclassifiable Interstitial Lung Disease: Time to Shrink the Black Box. ( 29957036 )
2018
12
Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. ( 29745875 )
2018
13
Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease. ( 29936470 )
2018
14
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. ( 29376545 )
2018
15
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? ( 29382307 )
2018
16
Granulomatous-lymphocytic interstitial lung disease at the emergency department: Think about it! ( 29970784 )
2018
17
Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report. ( 29338781 )
2018
18
The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. ( 29346191 )
2018
19
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
20
Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis. ( 29968330 )
2018
21
Risk factors for primary SjAPgren syndrome-associated interstitial lung disease. ( 29850114 )
2018
22
KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. ( 29961690 )
2018
23
Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. ( 29446698 )
2018
24
Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. ( 29607151 )
2018
25
Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary SjAPgren syndrome patients: A case-control study. ( 29901591 )
2018
26
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. ( 29422324 )
2018
27
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
28
Measures that matter: Health-related quality of life in children with interstitial lung disease. ( 29943900 )
2018
29
Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD). ( 29414453 )
2018
30
International management platform for children's interstitial lung disease (chILD-EU). ( 29056600 )
2018
31
Hepatopulmonary Syndrome and Diffuse Interstitial Lung Disease: An Unusual Combination. ( 29588084 )
2018
32
Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review. ( 29417209 )
2018
33
Prognosis of Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies: Look in the Middle. ( 29920503 )
2018
34
Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. ( 29348183 )
2018
35
Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. ( 29452423 )
2018
36
ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease. ( 29411180 )
2018
37
Transbronchial Lung Cryobiopsy for Diagnosis of Pediatric Interstitial Lung Disease. ( 29978822 )
2018
38
Interstitial lung disease and pre-capillary pulmonary hypertension in neurofibromatosis type 1. ( 29977746 )
2018
39
Could quality be the key in connective tissue disease-associated interstitial lung disease? ( 29897157 )
2018
40
Screening High Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. ( 29426066 )
2018
41
Interstitial lung disease in non-sicca onset primary SjAPgren's syndrome: a large-scale case-control study. ( 29968329 )
2018
42
Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. ( 29957270 )
2018
43
Advocating for early interstitial lung disease detection in mixed connective tissue disease. ( 28977485 )
2018
44
Pneumomediastinum Post EBUS-TBNA in Interstitial Lung Disease. ( 29944592 )
2018
45
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. ( 29343236 )
2018
46
Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility. ( 29938208 )
2018
47
Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. ( 29289262 )
2018
48
Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. ( 29413504 )
2018
49
Clinical and pathological characteristics of IgG4-related interstitial lung disease. ( 29434730 )
2018
50
Pulmonary manifestations in systemic lupus erythematosus: pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage. ( 29773465 )
2018

Variations for Interstitial Lung Disease

Expression for Interstitial Lung Disease

Search GEO for disease gene expression data for Interstitial Lung Disease.

Pathways for Interstitial Lung Disease

Pathways related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CCL2 CCL5 CXCL8 EGFR IFIH1 IL1A
2
Show member pathways
13.89 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
3
Show member pathways
13.83 ABCA3 CCL2 CXCL8 IFIH1 MUC1 MUC5B
4
Show member pathways
13.72 CCL17 CCL2 CCL5 CXCL8 EDN1 EGFR
5
Show member pathways
13.58 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
6
Show member pathways
13.4 CCL2 CCL5 CXCL8 EGFR IL1A IL1B
7
Show member pathways
13.4 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
8
Show member pathways
13.32 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
9
Show member pathways
13.07 CCL2 CCL5 CXCL8 EGFR IFIH1 IL1B
10
Show member pathways
13.05 CCL2 CCL5 CXCL8 IL1B SFTPD TGFB1
11
Show member pathways
12.81 CCL2 CCL5 CXCL8 IFIH1 IL1A IL1B
12 12.79 EGFR IL1A IL1B TGFB1 TNF
13
Show member pathways
12.78 CCL5 CXCL8 IFIH1 IL1B TNF
14
Show member pathways
12.73 EGFR IL1A IL1B TGFB1 TNF
15
Show member pathways
12.63 CCL2 EGFR IL1B ITGA3 TNF
16 12.61 CCL2 CCL5 IFIH1 IL1B TNF
17
Show member pathways
12.44 IL1A IL1B TGFB1 TNF
18
Show member pathways
12.35 CCL2 CCL5 IL1B TNF
19
Show member pathways
12.35 CCL17 CCL2 CXCL8 IL1B MUC5B TNF
20
Show member pathways
12.32 CXCL8 IL1A IL1B TNF
21
Show member pathways
12.32 CXCL8 EGFR IL1A IL1B TGFB1 TNF
22
Show member pathways
12.28 IL1A IL1B TGFB1 TNF
23 12.26 IL1A IL1B TGFB1 TNF
24
Show member pathways
12.26 CCL17 CCL2 CCL5 CXCL8 IL1A IL1B
25
Show member pathways
12.25 CXCL8 EDN1 EGFR IL1A IL1B MUC5B
26
Show member pathways
12.24 CXCL8 IL1B MUC1 SFTPD TNF
27 12.22 CXCL8 IL1A IL1B TF TNF
28 12.14 CCL2 EDN1 IL1A IL1B TNF
29
Show member pathways
12.11 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
30 12.09 IL1A IL1B TGFB1 TNF
31
Show member pathways
12.04 CCL17 CCL2 CCL5 CXCL8
32 12.03 CCL2 CXCL8 EGFR IL1A IL1B TGFB1
33 12 CXCL8 IL1A IL1B TGFB1
34 11.99 CCL2 CCL5 EDN1 IL1B TNF
35 11.95 IL1A IL1B ITGA3 TNF
36 11.94 CXCL8 IL1B TGFB1 TNF
37 11.92 CCL2 CXCL8 IL1A IL1B MUC1 TGFB1
38
Show member pathways
11.88 SFTPB SFTPC SFTPD
39 11.84 CXCL8 IL1A IL1B
40 11.83 CXCL8 IL1A IL1B TNF
41 11.77 IL1B TGFB1 TNF
42 11.76 CCL17 CCL2 CCL5 IL1B TGFB1 TNF
43
Show member pathways
11.73 CXCL8 IL1A IL1B TNF
44 11.7 CCL2 CXCL8 EDN1 IL1A IL1B TGFB1
45 11.63 CXCL8 IL1B TNF
46 11.6 CCL2 CXCL8 IL1B TGFB1 TNF
47 11.57 EGFR IL1B TGFB1 TNF
48 11.56 CCL2 IL1B TNF
49 11.53 IL1A IL1B TNF
50
Show member pathways
11.5 ABCA3 SFTPB SFTPC SFTPD

GO Terms for Interstitial Lung Disease

Cellular components related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 CCL17 CCL2 CCL5 CXCL8 EDN1 EGFR
2 extracellular space GO:0005615 9.55 ABCA3 CCL17 CCL2 CCL5 CXCL8 EDN1
3 endocytic vesicle GO:0030139 9.54 EGFR SFTPD TF
4 lamellar body GO:0042599 9.4 SFTPB SFTPC
5 clathrin-coated endocytic vesicle GO:0045334 9.33 SFTPB SFTPC SFTPD
6 multivesicular body lumen GO:0097486 9.32 SFTPB SFTPC
7 alveolar lamellar body GO:0097208 9.26 ABCA3 SFTPB

Biological processes related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.99 CCL17 CCL2 CCL5 CXCL8
2 cellular protein metabolic process GO:0044267 9.98 ABCA3 SFTPB SFTPC SFTPD TF
3 inflammatory response GO:0006954 9.97 CCL17 CCL2 CCL5 CXCL8 IL1A IL1B
4 MAPK cascade GO:0000165 9.95 CCL2 CCL5 EGFR IL1B TGFB1 TNF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 CCL17 CCL2 CCL5 EGFR IL1B TGFB1
6 animal organ morphogenesis GO:0009887 9.94 CCL2 NKX2-1 SFTPB TNF
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 EGFR TGFB1 TNF
8 cellular response to mechanical stimulus GO:0071260 9.91 EGFR IL1B TGFB1
9 regulation of insulin secretion GO:0050796 9.91 CCL5 IL1B TNF
10 cellular response to interferon-gamma GO:0071346 9.91 CCL17 CCL2 CCL5 EDN1
11 cellular response to tumor necrosis factor GO:0071356 9.91 CCL17 CCL2 CCL5 CXCL8 EDN1
12 response to glucocorticoid GO:0051384 9.9 ABCA3 IL1B TNF
13 cellular response to drug GO:0035690 9.9 EDN1 EGFR IL1B
14 positive regulation of epithelial cell proliferation GO:0050679 9.9 CCL5 EGFR TGFB1
15 positive regulation of protein localization to plasma membrane GO:1903078 9.88 EGFR ITGA3 TNF
16 chemokine-mediated signaling pathway GO:0070098 9.88 CCL17 CCL2 CCL5 CXCL8
17 positive regulation of cell division GO:0051781 9.87 IL1A IL1B TGFB1
18 positive regulation of MAP kinase activity GO:0043406 9.87 EDN1 EGFR TGFB1 TNF
19 monocyte chemotaxis GO:0002548 9.86 CCL17 CCL2 CCL5
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 EDN1 IL1B TNF
21 positive regulation of JUN kinase activity GO:0043507 9.85 EDN1 IL1B TNF
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 CCL5 EDN1 EGFR TNF
23 cellular response to interleukin-1 GO:0071347 9.85 CCL17 CCL2 CCL5 CXCL8 EDN1
24 positive regulation of phagocytosis GO:0050766 9.84 IL1B SFTPD TNF
25 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.84 IL1A IL1B TNF
26 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 EDN1 EGFR IL1B TNF
27 lymphocyte chemotaxis GO:0048247 9.83 CCL17 CCL2 CCL5
28 negative regulation of mitotic cell cycle GO:0045930 9.83 EGFR TGFB1 TNF
29 cellular response to organic cyclic compound GO:0071407 9.83 CCL2 CCL5 IL1B TGFB1 TNF
30 cellular response to fibroblast growth factor stimulus GO:0044344 9.81 CCL2 CCL5 CXCL8
31 positive regulation of mitotic nuclear division GO:0045840 9.8 EDN1 IL1A IL1B
32 positive regulation of vascular endothelial growth factor production GO:0010575 9.8 IL1A IL1B TGFB1
33 respiratory gaseous exchange GO:0007585 9.8 EDN1 SFTPB SFTPC SFTPD
34 negative regulation of myoblast differentiation GO:0045662 9.79 CCL17 TGFB1 TNF
35 positive regulation of neutrophil chemotaxis GO:0090023 9.78 CXCL8 EDN1 IL1B
36 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.75 CCL5 CXCL8
37 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.75 IL1A IL1B
38 PERK-mediated unfolded protein response GO:0036499 9.75 CCL2 CXCL8
39 response to dexamethasone GO:0071548 9.74 EDN1 IL1B
40 cerebral cortex cell migration GO:0021795 9.74 EGFR NKX2-1
41 neutrophil activation GO:0042119 9.74 CCL5 CXCL8
42 astrocyte activation GO:0048143 9.74 EGFR TNF
43 salivary gland morphogenesis GO:0007435 9.74 EGFR TGFB1
44 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.73 EGFR TGFB1
45 positive regulation of chemokine biosynthetic process GO:0045080 9.73 IL1B TNF
46 macrophage chemotaxis GO:0048246 9.73 CCL2 CCL5 SFTPD
47 ectopic germ cell programmed cell death GO:0035234 9.72 IL1A IL1B
48 positive regulation of prostaglandin secretion GO:0032308 9.72 EDN1 IL1B
49 protein kinase B signaling GO:0043491 9.72 CCL2 CCL5 IL1B TGFB1 TNF
50 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF

Molecular functions related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 CCL5 EGFR IFIH1 SFTPC SFTPD TGFB1
2 CCR chemokine receptor binding GO:0048020 9.5 CCL17 CCL2 CCL5
3 cytokine activity GO:0005125 9.28 CCL17 CCL2 CCL5 CXCL8 EDN1 IL1A
4 chemokine activity GO:0008009 9.26 CCL17 CCL2 CCL5 CXCL8
5 CCR4 chemokine receptor binding GO:0031729 9.16 CCL17 CCL5
6 protein binding GO:0005515 10.21 CCL17 CCL2 CCL5 CXCL8 EDN1 EGFR

Sources for Interstitial Lung Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....